Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | SNCA | P37840 | 2/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA3 | P07451 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | CA5A | P35218 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.58 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20455920 | 1.00 | KDM4E (0.69) | KDM4EALDH1A1SMN1; SMN2HPGDALOX15 | |
| SCHEMBL30289943 | 1.00 | KDM4E (0.69) | KDM4EALDH1A1SMN1; SMN2HPGDALOX15 | |
| SCHEMBL19695927 | 0.90 | FDPS (0.73) | KDM4EALDH1A1SMN1; SMN2HPGDALOX15 | |
| SCHEMBL12336758 | 0.90 | NFE2L2 (0.72) | KDM4EALDH1A1SMN1; SMN2HPGDALOX15 | |
| SCHEMBL20455947 | 0.88 | FDPS (0.56) | KDM4EALDH1A1SMN1; SMN2HPGDALOX15 | |
| SCHEMBL30289951 | 0.88 | FDPS (0.74) | KDM4EALDH1A1SMN1; SMN2HPGDALOX15 | |
| SCHEMBL20468262 | 0.88 | FDPS (0.74) | KDM4EALDH1A1SMN1; SMN2HPGDALOX15 | |
| SCHEMBL9901363 | 0.88 | FDPS (0.60) | KDM4EALDH1A1SMN1; SMN2HPGDALOX15 | |
| SCHEMBL9901361 | 0.88 | FDPS (0.60) | KDM4EALDH1A1SMN1; SMN2HPGDALOX15 | |
| SCHEMBL9901365 | 0.88 | FDPS (0.60) | KDM4EALDH1A1SMN1; SMN2HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11603349-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD (AU) | 2023-03-14 | — | — | US | disclosed |
| US-20210246100-A1 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD (AU) | 2021-08-12 | — | — | US | disclosed |
| US-11014873-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD. (AU) | 2021-05-25 | — | — | US | disclosed |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603349-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, TGFB2 | KDM4E 4055/4885ALDH1A1 1274/4885SMN1; SMN2 2749/4885 |
| US-20210246100-A1 | ANTI-FIBROTIC COMPOUNDS | TGFB1, SMAD3, TGFB2 | KDM4E 4055/4885ALDH1A1 1274/4885SMN1; SMN2 2749/4885 |
| US-11014873-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, SMAD2 | KDM4E 4041/4885ALDH1A1 1184/4885SMN1; SMN2 2869/4885 |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | TGFB1, SMAD3, SMAD2 | KDM4E 3305/4885ALDH1A1 1967/4885SMN1; SMN2 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.